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Abstract
The mTOR protein kinase is known to control cell cycle progression and cell growth through regulation of translation,
transcription, membrane traffic and protein degradation. Known interactions of mTOR do not account for the multiple
functions of this protein. Using a non-catalytic segment of mTOR (1^670) as bait in a yeast two-hybrid screen for interacting
proteins, ubiquilin 1 (NM013438) was identified. Ubiquilin 1 is a member of a phylogenetically conserved gene family of
unknown function, characterized by an N-terminal ubiquitin-like (Ubq) domain, a C-terminal ubiquitin associated (Uba)
domain and a central region containing numerous NPXB motifs (X, any; B, hydrophobic amino acid). GST-ubiquilin 1 binds
specifically to FLAG-mTOR (residues 1^670) in mammalian cells ; residues 570^670 of mTOR and 226^323 of ubiquilin 1 are
required for this interaction. Both mTOR and ubiquilin immunoreactivity appear as fine speckles throughout the cytoplasm;
significant colocalization with cytoskeletal elements, early endosomes or proteasomes is not observed. As assessed by cell
fractionation, mTOR is predominantly associated with low density membranes, along with 10% of ubiquilin 1. Ubiquilin 1 is
a rapamycin-insensitive phosphoprotein. Overexpression of ubiquilin 1 does not alter the kinase activity of cotransfected
mTOR or the phosphorylation of the mTOR target, p70 S6 kinase, in the presence or absence of rapamycin. Our data suggest
that we have identified a novel mTOR interactor, ubiquilin 1. The biological significance of this, presumably membrane
based, interaction, requires further study. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The TOR polypeptides (known variously as TOR,
FRAP, RAFT or RAPT) are giant protein kinases,
whose catalytic domain is most closely related to the
protein kinases MEC1 and TEL1 of Saccharomyces
cerevisiae and the mammalian protein kinases,
ATM, ATR, FRP1 and the DNA protein kinase
[1]. Taken together, these proteins are best charac-
terized as checkpoint control elements, which func-
tion to control cell cycle progression, in response to
changes in the integrity of cellular DNA and/or to
processes necessary for accurate cell division. The
biological functions of the TOR proteins have been
most fully characterized in S. cerevisiae through the
deletion of the two TOR genes or addition of rapa-
mycin.
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The response to mTOR best characterized thus far
in mammalian cells is in translational regulation. The
mTOR kinase can activate, among other factors, the
p70 S6 kinase through direct phosphorylation
(shown in vitro [2,3]), or through negative regulation
of an inactivating p70 S6K phosphatase, perhaps
PP2A [4], leading to the initiation of translation of
mRNAs containing 5P terminal oligopyrimidine mo-
tifs, most of which encode ribosomal proteins and
other translational components. Among other bio-
logical events controlled by an mTOR-responsive
pathway are autophagy [5], carbohydrate metabolism
[6,7], cell progression through G1 [8], and gene tran-
scription [9]. Recently published data suggest that
the known mTOR pathways could be a¡ected by
interactions mediated by other parts of mTOR than
the kinase domain; thus, the ability of mTOR to
signal to p70 S6 kinase appears to depend in part
on mTORs binding of gephyrin through the non-
catalytic region [10]. Gephyrin, ¢rst characterized
as a polypeptide necessary for the clustering of post-
synaptic glycine receptors, also appears to control
the localization of mTOR in HeLa cells, converting
the ¢ne punctuate cytoplasmic pattern of mTOR
immunoreactivity to a coarsely clumped one. In
an e¡ort to identify other proteins that interact
with the non-catalytic regions of mTOR, we used
mTOR (1^670) as bait in a two-hybrid screen and
recovered a single polypeptide, ubiquilin 1. This re-
port describes the interaction between mTOR and
ubiquilin 1, and subcellular localization of these
two polypeptides.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM),
heat-inactivated fetal calf serum, calf serum, L-gluta-
mine, penicillin-streptomycin, calyculin A and lipo-
fectamine were from Gibco BRL (Grand Island, NY,
USA). CNBr-activated Sepharose 4B, protein A-Se-
pharose and glutathione Sepharose beads were from
Amersham Pharmacia Biotech (Uppsala, Sweden).
Ultrafree-4 centrifugal ¢lter unit (10K cuto¡),
PVDF membrane (Immobilon-P) were from Milli-
pore (Bedford, MA, USA). Glycine, triethylamine,
Tris, Tween 20, EDTA, sucrose, rapamycin, mono-
clonal anti-lactate dehydrogenase (LDH) (clone HH-
17), anti-L-COP (clone mAD), anti-L-tubulin (clone
TUB 2.1), anti-vimentin (clone VIM 13.2) and anti-
FLAG antibodies were from Sigma (St. Louis, MO,
USA). The ‘Complete’ protease inhibitor cocktail
was from Boehringer Mannheim (Germany). Brad-
ford assay reagent and the DC protein assay reagents
were from Bio-Rad (Hercules, CA, USA). The hu-
man multiple tissue blots and the human placenta
pretransformed ‘Matchmaker’ cDNA Libraries,
yeast strain (YJ69-2A) were purchased from Clon-
tech (Palo Alto, CA, USA). Restriction enzymes
were from New England BioLabs (Beverly, MA,
USA). Random primer labeling kit was from Strata-
gene (La Jolla, CA, USA). SuperBlock blocking bu¡-
er was from Pierce (Rockford, IL, USA). The ECL
chemiluminescence ‘femtoLUCENT’ detection kit
was from Geno Technology (St. Louis, MO, USA).
Monoclonal anti-calnexin (clone 37) and anti-early
endosomal antigen A1 (EEA1) (clone 14) antibodies
were from Pharmingen/Transduction Laboratories
(San Diego, CA, USA); monoclonal anti-proteasome
K subunit antibodies were from Zymed (San Francis-
co, CA, USA). All £uorophore- or horseradish per-
oxidase-conjugated secondary antibodies were from
Jackson Immunoresearch (West Grove, PA, USA).
Alexa Fluor546 labeling kit was from Molecular
Probes (Eugene, OR, USA).
2.2. Cell culture
BHK-21, HEK-293, CHO and HeLa cells were
grown in DMEM supplemented with 10% heat-inac-
tivated fetal calf serum, 2 mM L-glutamine, 100 U/ml
penicillin-streptomycin at 37‡C in an atmosphere of
5% CO2. For the growth of NIH 3T3 and Swiss 3T3
cells, 10% calf serum was used. Cells were passaged
at subcon£uence.
2.3. Two-hybrid screen
A cDNA encoding mTOR (amino acids (aa) 1^
670) was subcloned into vector pGBDU-C1 (kindly
provided by Dr. Elizabeth Craig) carboxyl-terminal
to the Gal-4 DNA-binding domain to form the bait
construct: mTOR (aa 1^670)/pGBDU-C1. This bait
construct was transformed into yeast strain YJ69-2A
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[11]. The pretransformed Human Placenta ‘Match-
maker’ cDNA library was screened according to
the user’s manual. 5U107 diploids were plated out
on Ura-Leu-His selection plate. After 8 days, two
large colonies appeared. X-Gal ¢lter assay was per-
formed for those colonies and all showed strong blue
color.
2.4. DNA sequence analysis
cDNA inserts were sequenced by the dideoxynu-
cleotide chain termination procedure of Sanger et al.
[12].
2.5. Computer analysis
Analysis of sequence data, sequence comparisons
and data base searches were performed using DNA
Strider 1.2 software, GCG program and BLAST pro-
grams provided by the NCBI server at the National
Institutes of Health (Bethesda, MD, USA).
2.6. Northern blot analysis
A 2.1 kb ubiquilin 1 insert (nucleotides 40^2161,
see Fig. 1), which was released from pACTII by
cleaving with BamHI-XhoI, was labeled with
[Q-32P]dATP by random primer method according
to the procedure manual from Stratagene. Condi-
tions for hybridization and high stringency washing
of the membrane followed the manual protocol using
Express Hybridization solution from Clontech.
2.7. Production of antiserum against ubiquilin 1
Peptides corresponding to ubiquilin 1 C-terminus
(GDINAAIERLLGSQPS) and N-terminus (KVTV-
KTPKEKEE) were coupled to KLH and used to
immunize rabbits at Cocalico Biologicals (PA,
USA) at 2 week intervals. Antiserum was collected
at 10 day intervals after the second injection. For
immunoa⁄nity puri¢cation, peptide was coupled to
CNBr-activated Sepharose 4B, antiserum was passed
over the column and the column was extensively
washed. Antibody was collected after low (10 mM
glycine pH 2.5) and high pH (100 mM triethylamine,
pH 11.5) elutions and concentrated using an ‘Ultra-
free-4’ centrifugal ¢lter unit.
2.8. Tissue and cell line Western blot
Sprague^Dawley rats (50 Wg) were starved over-
night, and tissues were excised in the following or-
der: spleen, kidney, liver, lung, small intestine, heart,
skeletal muscle and brain. Cell lines were grown to
80^90% con£uence before harvesting. Both tissue
and cell lines were disrupted and extracted in RIPA
bu¡er (50 mM Tris^HCl, pH 7.4, 150 mM NaCl, 1%
NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sul-
fate and protease inhibitor cocktail).
2.9. Immunoblot analysis
The protein concentrations of the cell lysates were
determined by a Bradford assay. Equal amounts of
protein were loaded into an SDS^polyacrylamide gel
(7.5 or 12% acrylamide), resolved by electrophoresis,
and transferred to PVDF membrane. The membrane
was incubated for 20 min in SuperBlock bu¡er to
block non-speci¢c binding sites. Membranes were in-
cubated with the primary antibodies and then with
the secondary peroxidase-conjugated donkey anti-
rabbit (1:40 000) or donkey anti-mouse (1:25 000)
antibodies for 1 h at room temperature in Tris-bu¡-
ered saline with 0.1% Tween 20. Labeled proteins
were visualized using the ‘femtoLUCENT’ detection
kit.
2.10. Detection of mTOR-ubiquilin 1 association
COS-7 cells were plated at a density of 1.2U106/10
cm dish and transfected 24 h later with 12 Wg of
FLAG-mTOR (aa 1^670)/pCMV5 or empty vector
and 6 Wg of GST-ubiquilin 1 (aa 14^589)/pEBG or
empty vector using lipofectamine. 48 h post trans-
fection, the cells were washed with 1UPBS and lysed
in lysis bu¡er (50 mM Tris^HCl, pH 8.0, 120 mM
NaCl, 1 mM EDTA, 6 mM EGTA, 1 mM DTT, 20
mM NaF, 20 mM L-glycerophosphate, 25 nM caly-
culin A and protease inhibitor cocktail) containing
0.1% Triton X-100 (TX-100). Lysates were homoge-
nized with 20 strokes of a Dounce homogenizer and
spun at 15 000Ug for 20 min. Half of the superna-
tant was incubated with anti-FLAG M2 antibodies
and protein A-Sepharose beads and the other half
with glutathione beads for 3 h at 4‡C. The beads
were washed four times with washing bu¡er (50
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mM Tris^HCl, pH 8.0, 120 mM NaCl) containing
1% TX-100, and then boiled in 1USDS sample bu¡-
er. The extracted proteins were analyzed by immuno-
blotting as above.
2.11. In vivo phosphorylation of ubiquilin 1
CHO cells were transfected with 6 Wg of GST-
ubiquilin 1 (aa 14^589)/pEBG using lipofectamine.
48 h post transfection, the cells were starved for
12 h and then washed with phosphate-free medium
and labeled with 32P (0.5 mCi/ml) for 2 h. Sub-
sequently, the labeled cells were treated with or
without rapamycin for 30 min and then 10% serum
was added back to cells for 20 min. The cells were
then washed and lysed in lysis bu¡er containing 1%
TX-100. GST-ubiquilin 1 was precipitated by gluta-
thione beads, boiled in 1USDS sample bu¡er and
resolved on 10% SDS^PAGE gel. The gel was
stained with Coomassie blue and phosphorylation
of GST-ubiquilin 1 was monitored by autoradiogra-
phy.
2.12. HEK-293 cell fractionation by sucrose density
gradients (SDG)
All steps were performed at 4‡C or on ice. HEK-
293 cells grown in 150 mm culture dishes to con£u-
ence were harvested by scraping into homogenization
bu¡er containing 5 mM Tris^HCl (pH 7.4), 1 mM
EDTA, 0.25 M sucrose, 0.25 mM PMSF and ‘com-
plete’ inhibitor cocktail. Cells were homogenized
with 15 strokes of a Dounce homogenizer followed
by ¢ve passes through a 22-gauge needle and MgCl2
was added to 1 mM, and KCl to 0.1 M. Nuclei
and unbroken cells were removed by centrifugation at
1000Ug for 10 min in a Beckman JA-20 rotor. 1500^
1800 Wl of postnuclear supernatant were layered over
a stepwise gradient of 0.4^2.25 M sucrose bu¡ered
with 10 mM HEPES (pH 7.4). Gradients were cen-
trifuged (Beckman SW-28 rotor; 100 000Ug for
4.5 h); 500 Wl fractions were collected from the bot-
tom of the tube and boiled in Laemmli sample bu¡er
(¢nal concentration 1U). The pellet was resuspended
in lysis bu¡er. The protein concentration in each
fraction was determined using the DC protein assay.
Equal volumes of samples from the gradient frac-
tions were subjected to electrophoresis and Western
blotting with antibodies to calnexin (1:1000), LDH
(1:1000), and L-COP (1:1000).
For £otation analysis, fractions 8^13 and 14^19 of
the SDG were concentrated using a Millipore ‘Ultra-
free-4’ centrifugal ¢lter unit to a volume of approx.
170 Wl. Assay was done essentially as described [13]
except that a SW 40Ti (Beckman) rotor was used.
The pellet was resuspended in SDS sample bu¡er.
Aliquots of each fraction were subjected to immuno-
blotting (70 Wl).
2.13. Immuno£uorescence staining
Cells grown on coverslips were rinsed with PBS,
¢xed in methanol at 320‡C for 15 min, rinsed twice
with PBS and incubated for 30 min at room temper-
ature with the appropriate dilution of primary anti-
body in PBS. To visualize ubiquilin 1 and mTOR, we
used our a⁄nity puri¢ed antibodies (1/80 and 1/50
dilution, correspondingly). Microtubules were visual-
ized with a L-tubulin-speci¢c antibody, and inter-
mediate ¢laments with a vimentin-speci¢c antibody.
Proteosomes were visualized with monoclonal anti-
body to proteasome K subunits, and early endosomes
with antibody to EEA1. Coverslips were washed with
PBS, and incubated with labeled secondary antibod-
ies from corresponding species in appropriate combi-
nation: £uorescein or rhodamine X-conjugated don-
key anti-rabbit, Cy2 or rhodamine X-conjugated
donkey anti-mouse (all 1:450). After a rinse in
PBS, coverslips were mounted on a microscope slide.
For immunodetection blocking assay, ubiquilin 1 C-
or N-terminus antibody was incubated for 30 min
with 15U excess of immunizing peptide at 37‡C
with constant shaking. The solution was centrifuged
at 12 000Ug for 10 min and used for immunoblotting
or immuno£uorescence staining as described.
3. Results
We used the N-terminal 670 residues of mTOR
fused to the Gal4 DNA-binding domain as a bait
to screen pretransformed human placenta match-
maker cDNA library in a yeast two-hybrid system
as modi¢ed by Craig and colleagues [11]. Two
strongly interacting clones were isolated which were
of identical sequence, containing a 2.1 kb insert of a
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partial cDNA clone (nucleotides 40^2161, Fig. 1).
A search of the database revealed a 1988 bp
cDNA, identical in sequence, deposited directly in
the NCBI database under the name ubiquilin
(AF176069) and later designated ubiquilin 1
(NM013438). The validity of this interaction was fur-
ther supported by the demonstration that the ubiq-
uilin 1 insert, when swapped from the prey vector
into the bait vector (fused to the Gal4 DNA-binding
domain), was able to interact speci¢cally with mTOR
(1^670) expressed as a fusion with the Gal4 activa-
tion domain in the library vector. The cDNA se-
quence of our mTOR-interacting clone is 39 nucleo-
tides shorter at the 5P end, and 374 nucleotides
longer at the 3P end than the ubiquilin 1 sequence,
but is otherwise identical, with two exceptions; our
sequence (Fig. 1A) identi¢es nucleotides 374 and 375
as G and C respectively instead of C and G in the
ubiquilin sequence (making amino acid 125 Ser
rather than Thr). Secondly, we ¢nd a C (nucleotide
1762) that is absent in the ubiquilin sequence; this
additional C results in a C-terminal polypeptide se-
quence of LLGSQPS, which is identical to that
found in human ubiquilin 2 (Fig. 1B), the murine
ubiquilin homologues, PLIC1 and PLIC2, and the
Xenopus homologue, XDRP1 (not shown).
The putative open reading frame of our mTOR-
interacting clone, combined with N-terminal amino
acids of ubiquilin 1, is composed of 589 residues with
a calculated molecular mass of 65 kDa (Fig. 1A); we
retain the name of ubiquilin 1. The polypeptides
most similar to ubiquilin 1 are the rat DA41 (86%
identity) and murine PLIC1 (84%), followed by hu-
man ubiquilin 2 (75%), murine PLIC2 (69%), human
A1U (62%), Xenopus XDRP1 (59%); the human
ubiquilin 3 polypeptide (47%) is more divergent. Dro-
sophila (CG14224, 50% identity) and Caenorhabditis
elegans (F15C11.2, 38% identity) homologues are
also evident; the founding member of this polypep-
tide family, yeast DSK2, is smaller and less well con-
served (28% identity) (Fig. 1B). A pro¢le scan of the
ubiquilin 1 amino acid sequence reveals that the
N-terminus of ubiquilin 1 (amino acids 37^111 by
prosite pro¢le) has strong homology to ubiquitin
(38% identity) (UBQ domain) and the C-terminus
shows a high similarity to the ubiquitin associated
domain (UBA domain); the latter is thought to be
a ubiquitin-binding domain, as it is found in a vari-
ety of proteins whose function is related to ubiquitin
and the ubiquitination pathway, as well as in several
protein kinases [14]. The central part of the ubiquilin
1 protein is characterized by 18 repeats of the se-
quence motif NPXB where B is a hydrophobic amino
acid and X is any amino acid. The NPXB motifs
within this central region of ubiquilin 1 are highly
conserved; 12/18 of the NPXB motifs found in ubiq-
uilin 1 are conserved in the Drosophila homologue
and 14/18 in C. elegans F15C11.2. Most striking is
that the total number of such motifs is also highly
conserved; thus, both the Drosophila and C. elegans
homologues contain a total of 16 NPXB motifs, be-
cause in addition to those conserved with ubiquilin 1,
several NPXB motifs not found in ubiquilin 1 are
also present. This phenomenon is very prominent
in the Dictyostelium discoideum homologue, SonA,
which although only 31% identical to ubiquilin 1
contains 16 NPXB motifs, of which nine are con-
served in ubiquilin 1 and seven are unique. The yeast
DSK2 polypeptide, although considerably smaller
than ubiquilin 1, also contains eight NPXB motifs,
six of which appear to be conserved. In contrast, the
S. cerevisiae RAD23 UV excision repair protein,
although it contains an N-terminal ubiquitin-like do-
main, and a C-terminal UBA domain, lacks any
NPXB motifs. Among the vertebrate ubiquilin ho-
mologues, ubiquilin 3 is the most divergent, contain-
ing only 11 NPXB motifs. Thus the NPXB motif,
along with the ubiquitin-like (UBQ) and UBA do-
mains, appears to be a characteristic feature of the
ubiquilin/DSK2 family of polypeptides.
Ubiquilin 1 mRNA abundance and complexity in
human tissue were examined by Northern blot (Fig.
2A). A predominant mRNA band at 4 kb is evident
in all tissues examined, and bands of 3.0 and 2.6 kb
are evident in skeletal muscle, heart, brain, kidney
and liver, which are (in descending order) the tissues
with highest levels of ubiquilin 1 mRNA; these addi-
tional bands may represent di¡erent splice variants
of the ubiquilin 1 mRNA. This mRNA distribution
is generally similar to that reported for murine
PLIC1 [15], but di¡ers from PLIC2 which is primar-
ily expressed in smooth muscle; human ubiquilin 3 is
expressed exclusively in testes. A polyclonal antibody
was raised against a C-terminal peptide of ubiquilin
1 (aa 574^589) which is completely identical in se-
quence to the corresponding region of ubiquilin 2.
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Fig. 1. Molecular structure of ubiquilin 1 and some homologues. (A) Sequence of ubiquilin 1 cDNA and protein. The nucleotide se-
quence of ubiquilin 1 is shown. The derived amino acid sequence is presented below the corresponding DNA sequence. Single under-
line represents the UBA domain and double underline represents the UBQ domain. (B) Comparison of ubiquilin 1 with human ubiq-
uilin 2, Drosophila gene product CG14224, C. elegans gene product F15C11, D. discoideum gene product SonA and yeast DSK2,
whose sequences are derived from the NCBI database. The GCG command PILEUP was used to create the alignment which was ad-
justed further by eye. NPXB motifs are shown in bold.
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Fig. 1 (continued).
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Immunoblot of extracts prepared from di¡erent rat
tissues shows two major immunoreactive bands at
V75 kDa and V62 kDa in most rat tissues; preim-
mune sera show no immunoreactivity, and the im-
munizing peptide blocks completely all signals evi-
dent by blot and immunocytochemistry. The
highest levels of ubiquilin polypeptides are detected
in rat brain, spleen, and liver with barely detectable
levels in skeletal muscle, kidney and small intestine
(Fig. 2B). Extracts prepared from several cell lines
also show widely varying expression, with highest
levels in the two hamster-derived lines, CHO and
Fig. 2. Ubiquilin expression. (A) Expression of ubiquilin 1 mRNA in human tissues. A 2.1 kb cDNA fragment of ubiquilin 1 (nucleo-
tides 40^2161) was labeled with [Q-32P]dATP and used for probing ubiquilin 1 mRNA from various human tissues. The L-actin cDNA
was used as positive control. (B) Expression of ubiquilin 1 polypeptides in rat tissues and cell lines. (Upper) Protein expression of
ubiquilin 1 in rat tissues. (Lower) Protein expression of ubiquilin 1 in various cell lines. Equal amounts of protein (50 Wg) from di¡er-
ent tissues and di¡erent cell lines were loaded on the gel.
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Fig. 3. Characterization of the ubiquilin^mTOR interaction. (A) Interaction of ubiquilin 1 (aa 14^589) with mTOR (aa 1^670) in
vivo. The COS-7 cells were transfected with FLAG-mTOR (aa 1^670)/pCMV5 and pEBG empty vector (lane 1), FLAG-mTOR (aa
1^670)/pCMV5 and ubiquilin 1 (aa 14^589)/pEBG (lane 2) or pCMV5-FLAG empty vector and ubiquilin 1 (aa 14^589)/pEBG (lane
3). Half of the total cell lysate was incubated for 3 h with GSH-agarose beads and half anti-FLAG M2 antibody and protein A
beads. Subsequently, the beads were subjected to SDS^PAGE. Ubiquilin 1 expression was monitored by anti-GST blot and mTOR ex-
pression by anti-FLAG M2 blot. (B) Analysis of motifs necessary for interaction between ubiquilin 1 and mTOR by yeast two-hybrid
systems. (Upper) Interaction of indicated mTOR fragment with ubiquilin 1 in yeast two-hybrid systems. (Lower) Interaction of indi-
cated ubiquilin 1 fragments with mTOR (aa 1^670) in yeast two-hybrid systems. For HIS3 activity, +, growth or 3, no growth on
histidine-free medium.
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Fig. 4. Immunocytochemical characterization of ubiquilin. (A) Immuno£uorescence (left) and phase contrast (right) micrographs of
representative cells from six cell lines. Cells were immunostained for endogenous ubiquilin 1 simultaneously in the same antibody solu-
tion and images were acquired under the same conditions. The exception is HEK293 cells. (B) Ubiquilin 1 does not colocalize with
the cytoskeletal elements and is largely distinct from mTOR. Phase contrast (C,F) micrographs of two BHK-21 cells. The boxed areas
are shown in magni¢ed immuno£uorescence micrographs (A,B,D,E) of ubiquilin 1 (B,E), tubulin (A) and vimentin (D) immunostain-
ing. Bar, 10 Wm.
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BHK-21, and substantial levels in H4-II-E (rat hep-
atoma) and 3T3-L1 adipocytes. The 75 kDa band is
predominant in the CHO and BHK-21 extracts,
whereas a V62 kDa band is predominant in H4-II-
E cells. The 3T3-L1 adipocytes exhibit two bands,
one at 75 kDa and a second slightly larger polypep-
tide; the latter corresponds to the single faint band
seen in extracts prepared from the murine ¢broblasts,
NIH 3T3 and Swiss 3T3 cells. An antibody recogniz-
ing the ubiquilin 1 aa 38^47 (identical in ubiquilin 2)
was generated. The antibody speci¢cally recognized
recombinant ubiquilin 1, and reacted speci¢cally with
three polypeptide bands endogenous to BHK-21
cells; two corresponded in mobility to those stained
by the anti carboxy-terminal ubiquilin antibody, and
the third is approx. 40 kDa (not shown). Although
the bands visualized using these anti-peptide antibod-
ies are ubiquilin 1, ubiquilin 2 or both, the lack of an
antibody that distinguishes between these two poly-
peptides precludes any conclusion as to the relative
Fig. 5. Ubiquilin and mTOR distribution on sucrose density gradient fractionation. (A) Postnuclear supernatant of HEK-293 cells
was separated on a 0.4^2.25 M sucrose gradient and aliquots of the resulting fractions were subjected to SDS^PAGE and immunoblot
for calnexin, a marker for endoplasmic reticulum membranes, L-COP, a marker for low density trans-Golgi network membranes,
LDH, a cytoplasmic enzyme, ubiquilin 1/2 and mTOR. P, pellet ; fraction 1 is the highest density. (B) Sucrose gradient fractions 14^
19 (overlapping with L-COP) and fractions 8^13 (containing more dense membranes) were concentrated, adjusted to 70% sucrose,
overlaid with lighter sucrose (see Section 2) and centrifuged to equilibrium. Over 90% of mTOR in both fractions are associated with
membranes, whereas a minor fraction of ubiquilin 1 is bound to membranes.
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contribution of ubiquilin 1 versus 2, alternative
mRNA splice variants and proteolysis to these im-
munoblot patterns.
To verify that the interaction of mTOR (1^670)
with ubiquilin 1 as observed in the two-hybrid yeast
expression system also occurs during transient ex-
pression in mammalian cells, COS-7 cells were co-
transfected with plasmids encoding GST-ubiquilin 1
(14^589) and FLAG-tagged mTOR (1^670); each
tagged polypeptide was isolated and examined for
the speci¢c recovery of the other (Fig. 3A). The ex-
pression of GST and GST-ubiquilin 1 was assessed
by anti-GST and anti-FLAG M2 immunoblot re-
spectively. GST-ubiquilin 1 is speci¢cally coprecipi-
tated with FLAG-mTOR (1^670); reciprocally,
FLAG-mTOR is copuri¢ed speci¢cally with GST-
ubiquilin 1 (Fig. 3A). A series of mTOR (aa 1^670)
and ubiquilin 1 (aa 14^589) deletion mutants were
introduced into the yeast two-hybrid system to iden-
tify the protein segments necessary for interaction;
the results are summarized in Fig. 3B. A fragment
encoding mTOR aa 540^670 is able to bind ubiquilin
1; however, the fragment containing mTOR aa 540^
577 does not, indicating that mTOR aa 578^670 ap-
pear to be necessary for the binding to ubiquilin 1.
The ubiquilin 1 fragment aa 94^323 is able to bind to
mTOR, whereas the ubiquilin 1 fragment aa 14^226
is unable to interact with mTOR. Thus, it appears
that the binding of ubiquilin 1 to mTOR requires
ubiquilin 1 aa 226^323; there are three NPXB motifs
(including one NPF) within this region.
We have not succeeded in precipitating endoge-
nous or recombinant ubiquilin with full-length
mTOR; it is unclear whether this is attributable to
the low recovery of endogenous and recombinant
mTOR, or to a sequestration of the relevant
mTOR segment by an inter- or intramolecular inter-
action.
Fig. 7. Ubiquilin 1 overexpression does not a¡ect p70 S6K 412
phosphorylation level in response to rapamycin. CHO-IR cells
were transfected with either myc-p70 S6K/pCMV5 and
pCDNA3.1 empty vector or myc-p70 S6K/pCMV5 and HA-
ubiquilin 1/pCDNA3. The cells were treated with carrier
(3Rap) or 200 nM rapamycin (+Rap) for 30 min, and then
10% serum was added back to the media for 20 min. Expres-
sion of HA fusion proteins were checked with anti-HA blot
from total cell lysates (C). Myc-p70 S6K was immunoprecipi-
tated by anti-Myc antibody and protein A bead and then
checked with anti-Myc blot (A). Anti-p70 S6K 412 phosphate-
speci¢c antibodies from New England BioLabs were used to
check the 412 phosphorylation level of p70 S6K from immuno-
precipitated myc-p70 S6K (B).
Fig. 6. Ubiquilin 1 is a rapamycin-insensitive phosphoprotein.
CHO-IR cells were transfected with a GST-ubiquilin expression
vector and incubated with extracellular 32P as described in Sec-
tion 2. 32P-Labeled cells were treated with carrier (3Rap) or
200 nM rapamycin (+Rap) for 30 min, followed by the addi-
tion of serum to 10%. GST-ubiquilin 1 was isolated from cell
lysates by adsorption to GSH-agarose, eluted into SDS sample
bu¡er and subjected to SDS^PAGE. The expression of GST-
ubiquilin 1 is shown by Coomassie blue staining of the gel (B)
and phosphorylation of GST-ubiquilin 1 was monitored by
autoradiography (A). Rapamycin inhibition of mTOR was re-
£ected by the dephosphorylation of endogenous p70 S6K, mea-
sured by anti-p70 S6K Thr412 P-speci¢c immunoblot (C).
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We examined the intracellular localization of ubiq-
uilin 1 using the a⁄nity-puri¢ed antibody to the
ubiquilin C-terminus. The intensity of £uorescence
observed in various cell lines parallels the relative
abundance of ubiquilin polypeptides observed by im-
munoblot (Fig. 4A and 2B). In six cell lines exam-
ined, ubiquilin 1 exhibits a di¡usely speckled pattern
throughout the cytoplasm, with some suggestion of
perinuclear accumulation; the latter may, however,
re£ect the greater mass of the cell in this region.
Little immunoreactivity is seen within the nucleus;
some immunoreactivity is seen at the periphery of
the cells, perhaps re£ecting the increased cell thick-
ness in the ru¥es. Double staining for ubiquilin 1
and microtubules (Fig. 4BA;B) or vimentin intermedi-
ate ¢laments (Fig. 4BD;E) do not support the occur-
rence of signi¢cant colocalization of ubiquilin 1 with
cytoskeletal structures. Costaining of lysosomes (us-
ing LysoTracker Green DND-26, Molecular Probes),
mitochondria (using MitoTracker Red CMXRos,
Molecular Probes) or early endosomes (using anti-
EEA1 antibody) provides no evidence for ubiquilin
1 organellar localization (data not shown). Protea-
some immunoreactivity occurs in a di¡use pattern
of coarse cytoplasmic speckles, but colocalization
with ubiquilin is not evident (data not shown). The
cellular distribution of mTOR was evaluated using
an a⁄nity-puri¢ed polyclonal antiserum raised to
the C-terminal 88 amino acids of rat mTOR (ex-
pressed as a GST fusion in Escherichia coli). Immu-
noblots of extract from several cell lines using this
antibody exhibit a single polypeptide of molecular
mass s 200 kDa. The pattern of mTOR immuno-
£uorescence observed in BHK-21 cells is similar to
that reported previously for HeLa cells [10], and
resembles closely that of ubiquilin 1 (data not
shown).
To further de¢ne the localization of ubiquilin and
mTOR, the distribution of these two polypeptides
was examined after cell fractionation by di¡erential
and SDG centrifugation. About 50% of mTOR and
20% of ubiquilin 1 sediment at 3U106UgUmin; ex-
traction of the particulate fraction with RIPA bu¡er
solubilizes approx. 2/3 of the particulate mTOR and
2/3 of ubiquilin 1 immunoreactivity (data not
shown). Thus both polypeptides appear to have cy-
tosolic, membrane-associated and possibly cytoskele-
tal localizations. Their distribution was further eval-
uated by subjecting a postnuclear homogenate to
SDG centrifugation, under conditions wherein mem-
branes, but not the non-membrane proteins, sedi-
ment to near-equilibrium density (Fig. 5). The bulk
of ubiquilin immunoreactivity cosedimented with
LDH; however, a fraction of ubiquilin was observed
to sediment to densities well beyond LDH, usually
paralleling the distribution of L-COP. The mTOR
immunoreactivity was visualized continuously from
fractions containing LDH to fractions of the highest
density, the latter overlapping with calnexin immu-
noreactivity. More de¢nitive evidence for the mem-
brane association of mTOR and ubiquilin polypep-
tides was sought by overlaying pools of SDG
fractions with sucrose solutions of a lower density
and centrifuging to equilibrium (Fig. 5). The distri-
bution observed for the pool of fractions containing
cytosol showed that all LDH remained in the denser
sucrose as expected, as did all of the ubiquilin; by
contrast, approx. 3/4 of mTOR was recovered in the
lighter sucrose, as expected for a membrane-associ-
ated polypeptide. The behavior of ubiquilin and
mTOR present in the pool composed of the post-
LDH fractions di¡ered substantially. Over 90% of
mTOR immunoreactivity is found to migrate into
the lower density sucrose, indicating that essentially
all of the mTOR sedimenting in the post-LDH frac-
tions in the initial SDG is membrane bound; the
ubiquilin immunoreactivity in these SDG fractions,
representing about 20% of total cellular content, is
distributed equally between the upper and lower su-
crose layers. These analyses indicate that at least 70^
80% of cellular mTOR is membrane bound, whereas
only a minor fraction (6 10%) of cellular ubiquilin 1
is membrane associated. E¡orts to detect ubiquilin
coprecipitation with mTOR, solubilized with non-
ionic detergent from the membrane fractions were
unsuccessful, primarily due to the low amounts of
ubiquilin 1 remaining in this fraction.
Ubiquilin 1 is itself a phosphoprotein, as shown by
metabolic labeling with 32P during transient expres-
sion. Treatment of cells with rapamycin at concen-
trations su⁄cient to dephosphorylate p70 S6 kinase
Thr412 does not alter 32P incorporation into ubiqui-
lin (Fig. 6). In comparison to eIF-4E-BP1, mTOR
does not catalyze signi¢cant phosphorylation of
ubiquilin 1 in vitro (not shown). Coexpression of
recombinant ubiquilin with mTOR does not alter
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the level of either polypeptide, or the kinase activity
of recombinant mTOR in vitro toward eIF-4E-BP1
(not shown). A well-characterized action of mTOR is
in the control of the phosphorylation of the p70 S6
kinase; p70 Thr412 is a site of direct mTOR-cata-
lyzed phosphorylation, and is the p70 site most rap-
idly dephosphorylated in vivo upon addition of ra-
pamycin. Coexpression of p70 S6 kinase with
ubiquilin 1 does not alter p70 Thr412 phosphoryla-
tion or the rapamycin-induced dephosphorylation of
Thr412 in vivo (Fig. 7). Thus ubiquilin does not ap-
pear to serve as a substrate for mTOR; furthermore
overexpression of ubiquilin 1 does not appear to
modify mTOR abundance or kinase activity.
4. Discussion
The present work describes the ability of ubiquilin
1 to bind speci¢cally to a non-catalytic region of the
mTOR kinase. Nevertheless, it is clear that only a
minority of either polypeptide occurs in this complex
in the steady state. The large majority of mTOR is
membrane associated, whereas the ubiquilins are pri-
marily cytoplasmic polypeptides. Moreover,
although both proteins exhibit a ¢nely speckled pat-
tern on immunocytochemistry, there is very little co-
incidence in their staining. The evidence thus far in-
dicates that ubiquilin is not a target of the mTOR
kinase, or a regulator of mTOR abundance or kinase
activity toward translational targets. The functional
signi¢cance of the mTOR^ubiquilin interaction is
thus unclear, as is the function of the ubiquilin poly-
peptides. Nevertheless, mTOR is a pleiotypic e¡ec-
tor, and the possibility remains that ubiquilin 1
serves as a regulator or e¡ector of certain biochem-
ical actions of mTORs, other than those we have
examined. It may be signi¢cant that despite the mul-
tiple, well de¢ned functions of TOR in S. cerevisiae,
the only yeast homologue of ubiquilin is DSK2, a
polypeptide required for spindle pole body duplica-
tion [16]. No evidence currently available links yeast
TOR or mammalian ubiquilin to this function. The
lack of ubiquilin homologues in yeast other than
DSK2 may indicate that ubiquilins participate in
TOR-regulated functions unique to metazoans, as
in the case for the p70 S6 kinase. Alternatively, yeast
may express polypeptides that are functionally ho-
mologous to ubiquilins, but more poorly conserved
on a structural basis.
The biological roles for the ubiquilins proposed
thus far have been highly divergent. Mouse PLIC-1
and PLIC-2, which appear to be homologous to hu-
man ubiquilin 1 and 2 respectively, were discovered
as proteins that interact with the cytoplasmic tail of
CD47, an integrin-associated protein; the PLICs/
ubiquilin were proposed to mediate the interaction
of vimentin intermediate ¢laments with CD47 at
the plasma membrane [15]. Rat DA41, which is
probably ubiquilin 1, was isolated in a two-hybrid
screen using the putative tumor suppressor DAN, a
protein of unknown biochemical function [17]. The
Xenopus ubiquilin 1 XDRP1 was reported to be a
nuclear protein that interacts with N-terminal seg-
ment of cyclin A and inhibits cyclin degradation in
vitro [18]. Ubiquilin 2, also named Chap 1, was iso-
lated in a two-hybrid screen using Stch, an HSP 70
homologue that contains an ATPase domain, but
lacks the HSP70 carboxy-terminal peptide-binding
domain [19]. Stch binds to the central, NPXB-rich
sequence of ubiquilin 2 through a region near the
Stch carboxy-terminus that is highly conserved in
the HSP70 family [19]; this segment of Stch also
binds the HSP70-ADP releasing protein Sti1 [20^
22], whose central region contains numerous NP
and DP motifs, weakly related to those in ubiquilin.
Thus, it appears that the ubiquilins are capable of
interacting with a wide variety of proteins, but the
functional signi¢cance of these interactions and in
most cases the ubiquilin domains that mediate these
interactions are not known. Similarly, the ubiquilins
are widely distributed throughout the cell, perhaps
re£ecting the existence of numerous polypeptide
partners; the failure to identify a predominant cellu-
lar site of ubiquilin localization may simply re£ect
the existence of diverse binding partners.
The function and binding partners of the ubiquilin
NPXB motifs are not known. The NPXB is to be
distinguished from the NPXY motif, in that Tyr
was not identi¢ed within or adjacent to the NPXB
motifs in the ubiquilins and Ser or Thr is rarely ob-
served at the XB sites. By contrast, Ser/Thr occur not
infrequently at the 31 and +1 to +3 sites. Three of
18 NPXB motifs in ubiquilin 1/2 are NPF and all
members contain at least one NPF motif; the latter
motif forms the core-binding element to the protein
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domain known as the Eps15 homology (EH) do-
main, which is found in a variety of proteins in-
volved in endocytosis, vesicle sorting and cytoskeletal
architecture [23,24]. Nevertheless, the large number
of conserved NPXB motifs other than NPF in the
ubiquilins, together with the lack of multiple NPXB
motifs in proteins such as hRAB or hNUMB, that
contain 1^4 NPF motifs of established functional
signi¢cance, points to the existence of one or more
classes of NPXB-binding partners, apart from EH
domains.
In conclusion, we demonstrated an interaction,
probably membrane based, between ubiquilin 1 and
the non-catalytic segment of mTOR. Establishing the
function of the ubiquilins, a highly conserved poly-
peptide family, and the functional consequences of
the mTOR^ubiquilin interaction probably involves
exploring new functions of mTOR, other than those
currently known, and will provide interesting oppor-
tunities for future research.
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